Key takeaways
Etravirine (Intelence) and delavirdine (Rescriptor) are both medications used to treat HIV infections and belong to the same class of non-nucleoside reverse transcriptase inhibitors (NNRTIs). However, there are several differences between them. Etravirine (Intelence) is currently available as both a brand-name and generic medication, while delavirdine (Rescriptor) is no longer available in the United States. Etravirine is typically prescribed for people who have developed resistance to other HIV medications and is taken twice daily after meals. In contrast, delavirdine was discontinued due to low demand and the availability of newer treatments. Etravirine can cause side effects like changes in cholesterol levels and rash, and it interacts with many other medications. Delavirdine, on the other hand, was discontinued for business reasons rather than safety concerns. Etravirine is still a part of current HIV treatment regimens, whereas delavirdine is not used anymore.
